If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
President Lula has taken a neutral instance on the war in Ukraine while highlighting the human cost of the war, as well as its impact on food security, cost of living and global supply chains, among others, as he has stated the importance of a peace process led by non-directly or indirectly involved nations such as India, Indonesia and China. In January 2023, Lula stated that he was "against the occupation Russia has done in Ukraine" for which he was praised by the Ukrainian World Congress During his trip to the US in February 2023, Lula and US president Joe Biden jointly criticized Russia for its invasion of Ukraine. On 24 February 2023, Brazil voted to condemn Russia over its invasion of Ukraine at the UNGA. In April 2023, Lula commenting on peace negotiations said "Putin must not take the Ukrainian territory. Crimea might not be on the table, but when it comes to what he [Putin] invaded again, he must reconsider it", with some media outlets mistranslating his statements as urging Ukraine to give up Crimea to Russia. Lula has also insisted in seeking peace, which is a binding foreign policy principle under the current pacifist Constitution , as he turned down Brazilian military weaponry sales proposed by Germany and France to be sent to Ukraine. In April 2023, Lula stated after a state visit to China that "the United States needs to stop encouraging war and start talking about peace". U.S.
=== Analgesia and abuse liability === Recent studies indicate that targeting NOP is a promising alternative route to relieving pain without the deleterious side effects of traditional MOP-activating opioid therapies. In primates, specifically activating NOP through systemic or intrathecal administration induces long-lasting, morphine-comparable analgesia without causing itch, respiratory depression, or the reinforcing effects that lead to addiction in an intravenous self-administration paradigm; thus eliminating all of the serious side-effects of current opioid therapies. Several commonly used opioid drugs including etorphine and buprenorphine have been demonstrated to bind to nociceptin receptors, but this binding is relatively insignificant compared to their activity at other opioid receptors in the acute setting (however the non-analgesic NOPr antagonist SB-612,111 was demonstrated to potentiate the therapeutic benefits of morphine). Chronic administration of nociceptin receptor agonists results in an attenuation of the analgesic and anti-allodynic effects of opiates; this mechanism inhibits the action of endogenous opioids as well, resulting in an increase in pain severity, depression, and both physical and psychological opiate dependence following chronic NOPr agonist administration. Administration of the NOPr antagonist SB-612,111 has been shown to inhibit this process. More recently a range of selective ligands for NOP have been developed, which show little or no affinity to other opioid receptors and so allow NOP-mediated responses to be studied in isolation.
Haüy postulated, "to each specific substance with a well defined chemical composition, capable of existence in a crystalline form, there corresponds a shape that is specific and characteristic of that substance." In 1808 John Dalton published his atomic theory of matter. In Dalton's theory, there were four key assertions: "matter is made up of roughly spherical atoms, which were indivisible and indestructible; all atoms of a given element are identical in mass and properties; compounds are formed by a combination of two or more different kinds of atoms; and chemical reactions involve the rearrangement of atoms". In his book A New System of Chemical Philosophy, crystals are considered as a periodic arrangement of spherical atoms. However, Dalton stated that it was premature to form any theory of crystallization. Kuhn proposed Dalton's atomic theory as an example of a paradigm in which Dalton asserted that atoms can only combine in simple, whole-number ratios (law of multiple proportions). Under this new paradigm, any reaction which did not occur in fixed proportion could not be a chemical process. There was a contradiction between the crystallographic and chemical paradigms. Haüy's theory asserted that crystals were composed of polyhedral units stacked up in three dimensions without gaps; Dalton's theory, by contrast, implied that crystals were constructed by a periodic arrangement of spherical atoms in space.
=== GABA === At GABAergic synapses, the cycle is called the GABA-glutamine cycle. Here the glutamine taken up by neurons is converted to glutamate, which is then metabolized into GABA by glutamate decarboxylase (GAD). Upon release, GABA is taken up into astrocytes via GABA transporters and then catabolized into succinate by the joint actions of GABA transaminase and succinate-semialdehyde dehydrogenase. Glutamine is synthesized from succinate via the TCA cycle, which includes a condensation reaction of oxaloacetate and acetyl-CoA-forming citrate. Then the synthesis of α-ketoglutarate and glutamate occurs, after which glutamate is again metabolized into GABA by GAD. The supply of glutamine to GABAergic neurons is less significant, because these neurons exhibit a larger proportion of reuptake of the released neurotransmitter compared to their glutamatergic counterparts
Sources: en.wikipedia.org
=== Bead method === A common laboratory-scale mechanical method for cell disruption uses glass, ceramic, or steel beads, 0.1–2 mm (0.004–0.08 in) in diameter, mixed with a sample suspended in an aqueous solution. First developed by Tim Hopkins in the late 1970s, the sample and bead mix is subjected to high level agitation by stirring or shaking. Beads collide with the cellular sample, cracking open the cell to release the intracellular components. Unlike some other methods, mechanical shear is moderate during homogenization resulting in excellent membrane or subcellular preparations. The method, often called "bead beating", works well for all types of cellular material - from spores to animal and plant tissues. It is the most widely used method of yeast lysis, and can yield breakage of well over 50% (up to 95%). It has the advantage over other mechanical cell disruption methods of being able to disrupt very small sample sizes, process many samples at a time with no cross-contamination concerns, and does not release potentially harmful aerosols in the process. In the simplest example of the method, an equal volume of beads are added to a cell or tissue suspension in a test tube and the sample is vigorously mixed on a common laboratory vortex mixer. While processing times are slow, taking 3–10 times longer than that in specialty shaking machines, it works well for easily disrupted cells and is inexpensive.
== Overview of AIDA physiological model == AIDA has been described in detail in the medical / scientific / computing / diabetes literature. It incorporates a compartmental model that describes glucose-insulin interaction in people completely lacking endogenous insulin secretion — i.e. insulin-dependent patients with type 1 diabetes mellitus. The AIDA model contains a single extra-cellular glucose compartment into which glucose enters via both absorption from the intestine and glucose production from the liver. The model also contains separate compartments for plasma and 'active' insulin, the latter being responsible for glycemic control while insulin is removed from the former by liver degradation. Full details of the AIDA model are accessible from within the AIDA software package, and can be viewed and printed separately via the AIDA website.
=== Genetics === From 2005 to 2007, Curis and Procter & Gamble collaborated on developing a topical hedgehog agonist for hair loss; the agent did not meet safety standards, and the program was terminated. In 2008, researchers at the University of Bonn announced they have found the genetic basis of two distinct forms of inherited hair loss. They found the gene P2RY5 causes a rare, inherited form of hair loss called hypotrichosis simplex. It is the first receptor in humans known to play a role in hair growth. Researchers found that disruption of the gene SOX21 in mice caused cyclical hair loss. Research has suggested SOX21 as a master regulator of hair shaft cuticle differentiation, with its disruption causing cyclical alopecia in mice models. Deletion of SOX21 dramatically affects hair lipids.
Sources: en.wikipedia.org
== Etymology == The term Sensex was coined by Deepak Mohoni, a stock market analyst in 1989. BSE Sensitive Index then was at about 750 points. Sensex is a portmanteau of the words Sensitive and Index.
=== Deficiency === In humans methionine is an essential amino acid; cysteine is conditionally essential and may be synthesized from non-essential serine via sulfur salvaged from methionine. Sulfur deficiency is uncommon due to the ubiquity of cysteine and methionine in food. Isolated sulfite oxidase deficiency is a rare, fatal genetic disease caused by mutations to sulfite oxidase, which is needed to metabolize sulfites to sulfates.
In their annual violent crime index for the year 2001, the FBI recorded the deaths from the attacks as murder, in separate tables so as not to mix them with other reported crimes for that year. In a disclaimer, the FBI stated that "the number of deaths is so great that combining it with the traditional crime statistics will have an outlier effect that falsely skews all types of measurements in the program's analyses." New York City also did not include the deaths in their annual crime statistics for 2001.
=== Radioactive isotopes === The existence of isotopes was first suggested in 1913 by the radiochemist Frederick Soddy, based on studies of radioactive decay chains that indicated about 40 different species referred to as radioelements (i.e. radioactive elements) between uranium and lead, although the periodic table only allowed for 11 elements between lead and uranium inclusive. Several attempts to separate these new radioelements chemically had failed. For example, Soddy had shown in 1910 that mesothorium (later shown to be 228Ra), radium (226Ra, the longest-lived isotope), and thorium X (224Ra) are impossible to separate. Attempts to place the radioelements in the periodic table led Soddy and Kazimierz Fajans independently to propose their radioactive displacement law in 1913, to the effect that alpha decay produced an element two places to the left in the periodic table, whereas beta decay emission produced an element one place to the right. Soddy recognized that emission of an alpha particle followed by two beta particles led to the formation of an element chemically identical to the initial element but with a mass four units lighter and with different radioactive properties. Soddy proposed that several types of atoms (differing in radioactive properties) could occupy the same place in the table. For example, the alpha-decay of uranium-235 forms thorium-231, whereas the beta decay of actinium-230 forms thorium-230.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.